Piper Sandler has downgraded Achilles Therapeutics (NASDAQ:ACHL) to neutral in the wake of additional Phase 1/2 data from its CHIRON and THETIS studies for its precision T cell therapy.

Employees at Achilles Therapeutics are bracing themselves ... therapy programme and shutting down the phase 1/2a CHIRON and THETIS clinical trials. In a statement, chief executive Iraj Ali said ...

and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its ...

Your Artstor image groups were copied to Workspace. The Artstor website will be retired on Aug 1st. Open: Museum of New Zealand - Te Papa To... Open: Museum of New Zealand - Te Papa Tongarewa Achilles ...

000lb It was named after Achilles of Greek legend The story goes that Achilles was dipped by his mother Thetis in the River Styx, to make him invincible But she held him by his heel which remained ...

and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform ...

Corporate Updates Following the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical trials, the Company has enga Here is how Achilles ...